Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells

International Journal of Cancer

Volumn 132, Issue 10, 2013, Pages 2327-2338

  Adair, Robert A ^a   Scott, Karen J ^a   Fraser, Sheila ^a   Errington Mais, Fiona ^a   Pandha, Hardev ^b   Coffey, Matt ^c   Selby, Peter ^a   Cook, Graham P ^a   Vile, Richard ^a,d   Harrington, Kevin J ^e   Toogood, Giles ^a   Melcher, Alan A ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF SURREY   (United Kingdom)

^c ONCOLYTICS BIOTECH INC   (Canada)

^d MAYO GRADUATE SCHOOL   (United States)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

colorectal liver metastases; interferon dependent; NK cells; reovirus

Indexed keywords

INTERFERON; NEUTRALIZING ANTIBODY; ONCOLYTIC VIRUS;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD CELL; CANCER CELL; CELL ACTIVATION; CELL KILLING; CELL STIMULATION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; EFFECTOR CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; INNATE IMMUNITY; LIVER CELL; LIVER METASTASIS; NATURAL KILLER CELL; NONHUMAN; ONCOLYTIC VIROTHERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTECTION; REOVIRUS; VIRUS NEUTRALIZATION;

ADENOCARCINOMA; BLOOD; CELL LINE, TUMOR; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HEPATOCYTES; HUMANS; INFUSIONS, INTRAVENOUS; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LIVER; LIVER NEOPLASMS; ONCOLYTIC VIROTHERAPY; PHENOTYPE; REOVIRIDAE;

EID: 84874937343     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27918     Document Type: Article

References (33)

1. Yap TA, Brunetto A, Pandha H, et al. Reovirus therapy in cancer: has the orphan virus found a home? Expert Opin Investig Drugs 2008; 17: 1925-35.
2. Prestwich RJ, Harrington KJ, Pandha HS, et al. Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther 2008; 8: 1581-8.
3. Seymour LW, Cawood R, Fisher KD,. Cellular carriers or free viruses? Curr Opin Mol Ther 2008; 10: 321-2.
4. Errington F, Steele L, Prestwich R, et al. Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol 2008; 180: 6018-26.
5. Errington F, White CL, Twigger KR, et al. Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Ther 2008; 15: 1257-70.
6. Prestwich RJ, Errington F, Ilett EJ, et al. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res 2008; 14: 7358-66.
7. White CL, Twigger KR, Vidal L, et al. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (dearing type 3) during a phase I clinical trial. Gene Ther 2008; 15: 911-20.
8. Prestwich RJ, Errington F, Steele LP, et al. Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J Immunol 2009; 183: 4312-21.
9. Prestwich RJ, Ilett EJ, Errington F, et al. Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin Cancer Res 2009; 15: 4374-81.
10. Steele L, Errington F, Prestwich R, et al. Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is pkr/nf-kappab mediated and supports innate and adaptive anti-tumour immune priming. Mol Cancer 2011; 10: 20.
11. Stoeckel J, Hay JG,. Drug evaluation: reolysin-wild-type reovirus as a cancer therapeutic. Curr Opin Mol Ther 2006; 8: 249-60.
12. Harrington KJ, Vile RG, Melcher A, et al. Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev 2010; 21: 91-8.
13. Power AT, Bell JC,. Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy. Gene Ther 2008; 15: 772-9.
14. Willmon C, Harrington K, Kottke T, et al. Cell carriers for oncolytic viruses: fed ex for cancer therapy. Mol Ther 2009; 17: 1667-76.
15. Nandan MO, Yang VW,. Genetic and chemical models of colorectal cancer in mice. Curr Colorectal Cancer Rep 2010; 6: 51-59.
16. Hirasawa K, Nishikawa SG, Norman KL, et al. Oncolytic reovirus against ovarian and colon cancer. Cancer Res 2002; 62: 1696-701.
17. Vidal L, Pandha HS, Yap TA, et al. A phase I study of intravenous oncolytic reovirus type 3 dearing in patients with advanced cancer. Clin Cancer Res 2008; 14: 7127-37.
18. Errington F, Jones J, Merrick A, et al. Fusogenic membrane glycoprotein-mediated tumour cell fusion activates human dendritic cells for enhanced IL-12 production and t-cell priming. Gene Ther 2006; 13: 138-49.
19. Barton ES, Forrest JC, Connolly JL, et al. Junction adhesion molecule is a receptor for reovirus. Cell 2001; 104: 441-51.
20. Hewitt RE, McMarlin A, Kleiner D, et al. Validation of a model of colon cancer progression. J Pathol 2000; 192: 446-54.
21. Clarke P, Tyler KL,. Reovirus-induced apoptosis: a minireview. Apoptosis 2003; 8: 141-50.
22. Qiao J, Kottke T, Willmon C, et al. Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive t cell therapy, oncolytic virotherapy and immunotherapy. Nat Med 2008; 14: 37-44.
23. Ilett EJ, Prestwich RJ, Kottke T, et al. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene Ther 2009; 16: 689-99.
24. Ilett EJ, Barcena M, Errington-Mais F, et al. Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization. Clin Cancer Res 2011; 17: 2767-76.
25. Andrews DM, Andoniou CE, Scalzo AA, et al. Cross-talk between dendritic cells and natural killer cells in viral infection. Mol Immunol 2005; 42: 547-55.
26. Gollamudi R, Ghalib MH, Desai KK, et al. Intravenous administration of reolysin(r), a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs 2009; 28: 642-9.
27. Burt BM, Plitas G, Zhao Z, et al. The lytic potential of human liver nk cells is restricted by their limited expression of inhibitory killer Ig-like receptors. J Immunol 2009; 183: 1789-96.
28. Li Z, Diehl AM,. Innate immunity in the liver. Curr Opin Gastroenterol 2003; 19: 565-71.
29. Donnelly OG, Errington-Mais F, Prestwich R, et al. Recent clinical experience with oncolytic viruses. Curr Pharm Biotechnol 2012; 13: 1834-41.
30. Adair RA, Roulstone V, Scott KJ, et al. Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci Transl Med 2012; 4: 138ra77.
31. Selb B, Weber B,. A study of human reovirus IgG and IgA antibodies by ELISA and western blot. J Virol Methods 1994; 47: 15-25.
32. Comins C, Spicer J, Protheroe A, et al. Reo-10: a phase 1 study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res 2010; 16: 5564-72.
33. Lopez-Nevot MA, Esteban F, Ferron A, et al. HLA class i gene expression on human primary tumours and autologous metastases: demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas. Br J Cancer 1989; 59: 221-6.